Skip to content
You are now leaving https://www.ionispharma.com to visit

Akcea and Ionis Report Positive Data from Phase 2 Study of AKCEA-APO(a)-LRx

Study demonstrates significant Lp(a) reduction, favorable safety and tolerability profile Largest and longest study of Ionis’ LICA technology Data to be presented as a late-breaking clinical trial presentation at AHA on November 10 in Chicago CAMBRIDGE, Mass. and CARLSBAD, Calif., Sept.